Vertex Pharmaceuticals Deal History & Licensing Activity
Vertex Pharmaceuticals is a large biotech headquartered in US. Over the past three years, Vertex Pharmaceuticals has been involved in 6 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 37 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
37
Top Modality
Other
Focus Area
Rare Disease
Vertex Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Vertex Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Hypercon™ | Halozyme Therapeutics | Other | Unknown | collaboration | Apr 2026 |
| War-Lock Drug Conjugates | Enlaza Therapeutics | ADC | Preclinical | co development | Sep 2025 |
Vertex Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Vertex Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Vertex Pharmaceuticals Strategic Signals
Key indicators of Vertex Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Vertex Pharmaceuticals Clinical Pipeline
Vertex Pharmaceuticals has 37 active clinical trials across 5 development phases.
2
Phase 4
1
Unknown
10
Phase 1
7
Phase 2
17
Phase 3
See How Your Asset Matches Vertex Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Vertex Pharmaceuticals Licensing & Deal Activity
Vertex Pharmaceuticals is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Vertex Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Vertex Pharmaceuticals include Rare Disease (16 deals and trials), Metabolic (5 deals and trials), CNS Disorders (5 deals and trials), and Other (3 deals and trials). In terms of modality, Vertex Pharmaceuticals has shown particular interest in other, adc, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Vertex Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Vertex Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.